Open AccessProtease Inhibitor and Nonnucleoside Reverse Transcriptase Inhibitor Concentrations in the Genital Tract of HIV-1-Infected Women
Author(s) -
Sherene Min,
Amanda Corbett,
Naser L. Rezk,
Susan CuUvin,
Susan A. Fiscus,
Leslie Petch,
Myron S. Cohen,
Angela D. M. Kashuba
Publication year - 2004
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/00126334-200412150-00008
Subject(s) - pharmacokinetics , reverse transcriptase inhibitor , protease inhibitor (pharmacology) , medicine , human immunodeficiency virus (hiv) , female circumcision , reverse transcriptase , pharmacology , confounding , virology , viral load , immunology , viral disease , biology , sida , gynecology , antiretroviral therapy , polymerase chain reaction , biochemistry , gene
The pharmacokinetics of antiretrovirals (ARVs) in the female genital tract (FGT) are likely to influence vertical and sexual transmission of HIV, the development of viral resistance, and post-exposure prophylaxis regimens. This study is the first to compare ARV concentrations in direct aspirates of cervicovaginal fluid (CVF) and blood plasma (BP). This unique method provides direct assessment of concentrations without the confounding of cervicovaginal lavage dilution. Of 8 ARVs, CVF concentrations ranged from <10% to >100% of BP concentrations. These large differences in CVF penetration suggest that further research into ARV pharmacokinetics and drug efficacy in the FGT is necessary.